Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1042 - Clinical course comparison between patients with type 1 and type 2 uterine endometrial cancers


18 Dec 2016


Poster lunch


Yae Takehara


Annals of Oncology (2016) 27 (suppl_9): ix94-ix103. 10.1093/annonc/mdw585


Y. Takehara1, M. Yunokawa1, S. Sasada1, E. Noguchi1, A. Shimomura1, T. Shimoi1, K. Yonemori1, C. Shimizu1, T. Kato2, K. Tamura1

Author affiliations

  • 1 Breast And Medical Oncology / Rare Cancer Center, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 2 Gynecology, National Cancer Center Hospital, 104-0045 - Tokyo/JP


Abstract 1042


Uterine endometrial cancer is classified into two groups: type 1, which includes grades 1 and 2 endometrial carcinoma; and type 2, which includes grade 3 endometrial carcinoma, serous adenocarcinoma, clear cell carcinoma, and mucinous carcinoma. No studies assessing optimal surveillance after initial treatment for endometrial cancer have been performed. This study aimed to determine the association between cancer type and recurrence time as well as the effect of prognostic factors.


Charts for patients with endometrial cancer who underwent surgery between January 2005 and December 2011 were retrospectively reviewed, and clinicopathological features and clinical courses were compared between patients with type 1 and type 2 disease. Cumulative incidence curves for recurrence were estimated, and the association between the time of relapse and cancer type was assessed by multivariate logistic regression.


Three hundred seventeen patients with type 1 disease and 106 patients with type 2 disease were evaluable. Advanced stage (stage III or IV) was more commonly found among patients with type 2 endometrial cancer (12% vs. 30.2%, p 


Type 2 of endometrial cancer recurred earlier than type 1 disease. More careful surveillance after initial treatment is needed for patients with type 2 endometrial cancer, especially in the first 2 years.

Clinical trial indentification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings